
Embedded health records inside the apps people already use.
Confirmed by founderSee something off about this company?
Alenio Health is embedded health record infrastructure for the apps consumers in Latin America already use every day. Instead of competing for downloads in a market where standalone health apps face punishing acquisition costs and weak retention, Alenio integrates inside the financial, telecom, and marketplace platforms that already own consumer trust. Partners gain a turnkey healthcare line of business. Consumers get a portable, patient-controlled health record built to US data security standards. Alenio captures distribution to tens of millions of users with zero per-user acquisition cost. The model is built on three durable advantages. Distribution is locked through partner integrations rather than paid acquisition. Compliance is built to US healthcare standards from day one, a moat that Latin America-native competitors will spend years closing. The free tier drives adoption inside partner ecosystems and converts to premium subscriptions at roughly 85 percent margin after partner royalty. Telehealth and AI-powered care tools layer on top as ARPU expansion, not the core bet. Toka FinTech is the beachhead. Alenio is working directly with Toka leadership and their innovation team to define a feature-specific build embedded inside Toka's consumer platform, with a sandbox handoff targeted for summer. Toka alone unlocks 19 million endpoints. Active conversations with Claro and Telcel cover an additional 80 million endpoints behind that. The math works fast. At $2.83 USD (about 50 MXN) per month in Mexico, only 30,000 paying subscribers are needed to cross $1M ARR. Inside Toka alone, that is less than 0.2 percent conversion. Alenio Health is raising $2M on SAFEs at a $10M post-money valuation cap, converting on $5M of qualifying round financing. Use of funds: ship the first partner integration, complete legal and compliance work for cross-border deployment, and reach the first paid subscriber milestone.